CVS Health's Caremark Unit Leads in Driving Down Prescription Costs Through Competition.

CVS Health is dominating the Pharmacy Benefit Manager market with Caremark tracking at a 90% retention rate. The company is driving down prescription and pharmacy costs by increasing competition through partnerships and formulary actions, such as preferring Novo Nordisk's Wegovy over Eli Lilly's Zepbound. CVS expects this decision could save 10-15% year over year in the anti-obesity medication space for members. The company is also set to provide outpatient prescription drug benefits for 587,000 CalPERS members starting January 1, 2026. CVS stock has surged 67.4% year-to-date and is trading at a forward five-year P/E of 10.87X, lower than the industry average.

CVS Health Corporation (NYSE: CVS) has solidified its position as a leader in the Pharmacy Benefit Manager (PBM) market, with Caremark achieving a 90% retention rate. This dominance is driven by strategic partnerships and formulary actions aimed at increasing competition and reducing costs. Notably, CVS is preferring Novo Nordisk's Wegovy over Eli Lilly's Zepbound for anti-obesity medications, a move that could save members 10-15% annually. Additionally, CVS will provide outpatient prescription drug benefits for 587,000 CalPERS members starting January 1, 2026.

The company's stock has surged by 67.4% year-to-date, trading at a forward five-year P/E of 10.87X, which is lower than the industry average. This performance underscores investor confidence in CVS Health's ability to navigate the competitive pharmaceutical market and deliver value to shareholders.